摘要
目的:系统评价利奈唑胺致血小板减少的危险因素,为临床合理用药提供参考。方法:计算机检索PubMed、Embase、Cochrane图书馆、Web of Science、中国生物医学文献数据库、中国知网和万方数据,检索时限均为建库起至2018年10月,收集利奈唑胺致血小板减少危险因素的临床研究,对符合标准的文献进行资料提取,并采用纽卡斯尔-渥太华质量评估量表(NOS)对纳入文献进行质量评价后,采用Rev Man 5.3软件进行Meta分析。结果:共纳入16项临床研究,合计2 264例患者。Meta分析结果显示,日公斤剂量高[SMD=0.62,95%CI(0.29,0.95),P=0.000 2]、用药前血小板计数低[SMD=-0.90,95%CI(-1.62,-0.18),P=0.01]、肌酐清除率低[SMD=-0.65,95%CI(-1.10,-0.19),P=0.005]、疗程长[SMD=0.45,95%CI(0.18,0.71),P=0.000 9]、体质量低[SMD=-0.36,95%CI(-0.60,-0.11),P=0.005]对血小板减少的发生均有显著影响。结论:血小板基础值低、肌酐清除率低、体质量低,用药疗程长和日公斤剂量高是利奈唑胺致血小板减少的危险因素。
OBJECTIVE:To evaluate risk factors of linezolid-induced thrombocytopenia systematically,and to provide reference for rational drug use in clinic.METHODS:Retrieved from PubMed,Embase,Cochrane library,Web of Science,CBM,CNKI and Wanfang database,during database establishment to Oct.2018,clinical studies about risk factors of linezolid-induced thrombocytopenia were collected,and the data of literatures met criteria were collected.After Newcastle-Ottawa scale(NOS)was applied for evaluating the quality of included literatures.Meta-analysis was conducted by using Rev Man 5.3 software.RESULTS:Sixteen clinical studies involving 2 264 patients in total were included.Results of Meta-analysis showed that daily per kg dose(DKPD)[SMD=0.62,95%CI(0.29,0.95),P=0.000 2],low platelet count before medication [SMD=-0.90,95%CI(-1.62,-0.18),P=0.01],low creatinine clearance rate [SMD=-0.65,95% CI(-1.10,-0.19),P=0.005],long treatment course [SMD=0.45,95% CI(0.18,0.71),P=0.000 9],low body weight [SMD=-0.36,95% CI(-0.60,-0.11),P=0.005] significantly influenced the occurrence of thrombocytopenia.CONCLUSIONS:The risk factors associated with linezolid-induced thrombocytopenia include low baseline platelet count,low creatinine clearance rate,low body weight,long medication course and high DKPD.
作者
白浩
孙朴
陈开杰
BAI Hao;SUN Pu;CHEN Kaijie(Dept.of Pharmacy,the Affiliated Cancer Hospital of Chongqing University,Chongqing 400030,China;Dept.of Scientific Education,the Affiliated Cancer Hospital of Chongqing University,Chongqing 400030,China;Dept.of Medical Administration,the Affiliated Cancer Hospital of Chongqing University,Chongqing 400030,China)
出处
《中国药房》
CAS
北大核心
2019年第7期980-984,共5页
China Pharmacy
基金
重庆市技术创新与应用示范(社会民生类)一般项目(No.cstc2018jscx-msybX0138)
